Ryvu Therapeutics SA (RVU) - Total Liabilities

Latest as of March 2026: zł159.63 Million PLN ≈ $43.93 Million USD

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has total liabilities worth zł159.63 Million PLN (≈ $43.93 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Ryvu Therapeutics SA - Total Liabilities Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. See RVU working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Ryvu Therapeutics SA Competitors by Total Liabilities

The table below lists competitors of Ryvu Therapeutics SA ranked by their total liabilities.

Company	Country	Total Liabilities
Evergreen Max Cash Capital Berhad KLSE:0286	Malaysia	RM128.30 Million
Aris Gold Corporation V:CGC	Canada	CA$2.10 Million
Answear.com S.A. WAR:ANR	Poland	zł641.88 Million
Semen Baturaja Persero Tbk JK:SMBR	Indonesia	Rp1.30 Trillion
Finder Energy Holdings Ltd AU:FDR	Australia	AU$891.40K
q.beyond AG F:QBY	Germany	€37.75 Million
Sao Mai Group Corp VN:ASM	Vietnam	₫15.29 Trillion
Bundamedik Tbk PT JK:BMHS	Indonesia	Rp1.62 Trillion

Liability Composition Analysis (2010–2025)

This chart breaks down Ryvu Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RVU stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.26	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.86	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.79	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ryvu Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual total liabilities of Ryvu Therapeutics SA from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	zł170.60 Million ≈ $46.95 Million	-27.37%
2024-12-31	zł234.89 Million ≈ $64.65 Million	+63.56%
2023-12-31	zł143.61 Million ≈ $39.52 Million	+9.14%
2022-12-31	zł131.59 Million ≈ $36.21 Million	+121.55%
2021-12-31	zł59.39 Million ≈ $16.35 Million	-17.42%
2020-12-31	zł71.92 Million ≈ $19.79 Million	+13.92%
2019-12-31	zł63.13 Million ≈ $17.38 Million	+3.77%
2018-12-31	zł60.84 Million ≈ $16.74 Million	+53.72%
2017-12-31	zł39.58 Million ≈ $10.89 Million	+18.46%
2016-12-31	zł33.41 Million ≈ $9.19 Million	+81.95%
2015-12-31	zł18.36 Million ≈ $5.05 Million	+4.63%
2014-12-31	zł17.55 Million ≈ $4.83 Million	+18.19%
2013-12-31	zł14.85 Million ≈ $4.09 Million	+51.28%
2012-12-31	zł9.82 Million ≈ $2.70 Million	+62.45%
2011-12-31	zł6.04 Million ≈ $1.66 Million	-31.08%
2010-12-31	zł8.77 Million ≈ $2.41 Million	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$91.37 Million

zł332.01 Million PLN

Market Cap Rank

#19640 Global

#158 in Poland

Share Price

zł14.36

Change (1 day)

-2.58%

52-Week Range

zł14.20 - zł32.40

All Time High

zł75.00